Sensitive liquid chromatography tandem mass spectrometry method for the quantification of sitagliptin, a DPP-4 inhibitor, in human plasma using liquid-liquid extraction

Biomedical Chromatography

Volumn 22, Issue 2, 2008, Pages 214-222

  Nirogi, Ramakrishna ^a   Kandikere, Vishwottam ^a   Mudigonda, Koteshwara ^a   Komarneni, Prashanth ^a   Aleti, Raghupathi ^a   Boggavarapu, Rajeshkumar ^a  

^a SUVEN LIFE SCIENCES LTD   (India)

Author keywords

DPP 4 inhibitor; Human plasma; Liquid chromatography tandem mass spectrometry; Pharmacokinetic study; Sitagliptin

Indexed keywords

HIGH PRESSURE LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; PHARMACOKINETICS; PLASMA (HUMAN); POSITIVE IONS;

DPP-4 INHIBITOR; HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN PLASMA SAMPLES; HUMAN PLASMAS; LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY; LIQUID CHROMATOGRAPHY/TANDEM MASS SPECTROMETRY; LIQUID-LIQUID EXTRACTION; PHARMACOKINETIC STUDIES; SENSITIVE LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY; SITAGLIPTIN;

HIGH PERFORMANCE LIQUID CHROMATOGRAPHY;

DIPEPTIDYL PEPTIDASE IV INHIBITOR; FLUOXETINE; SITAGLIPTIN;

ACCURACY; ARTICLE; BLOOD SAMPLING; DRUG STRUCTURE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIQUID LIQUID EXTRACTION; MONITORING; PLASMA; QUANTITATIVE ANALYSIS; TANDEM MASS SPECTROMETRY; VALIDATION PROCESS;

EID: 39349105566     PISSN: 02693879     EISSN: 10990801     Source Type: Journal    
DOI: 10.1002/bmc.926     Document Type: Article

References (8)

1. Bergman A, Ebel D, Liu F, Stone J, Wang A, Zeng W, Chen L, Dilzer S, Lasseter K, Herman G, Wagner J and Krishna R. Absolute bioavailability of sitagliptin, an oral dipeptidyl peptidase-4 inhibitor, in healthy volunteers. Biopharmaceutics and Drug Disposition 2007; 28: 315.
2. Gallwitz B. Review of sitagliptin phosphate: a novel treatment for type 2 diabetes. Vascular Health and Risk Management 2007; 3: 203.
3. Herman GA, Stevens C, Dyck KV, Bergman A, Yi B, Smet M, Snyder K, Hilliard D, Tanen M, Tanaka W, Wang AQ, Zeng W, Musson D, Winchell G, Davies M, Ramael S, Gottesdiener KM and Wagner JA. Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses. Clinical Pharmacology and Therapeutics 2005; 78: 675.
4. Herman GA, Stein PP, Thornberry NA and Wagner JA. Dipeptidyl peptides-4 inhibitors for the treatment of type 2 diabetes: focus on sitagliptin. Clinical Pharmacology and Therapeutics 2007; 81: 761.
5. Lyseng-Williamson KA. Sitagliptin. Drugs 2007; 67: 587.
6. Matuszewski BK, Constanzer ML and Chavez-Eng CM. Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS. Analytical Chemistry 2003; 75: 3019.
7. 14C]Sitagliptin in humans. Drug Metabolism and Disposition 2007; 35: 533.
8. Zeng W, Musson DG, Fisher AL and Qang AQ. Determination of MK-0431 in human plasma using high turbulence liquid chromatography online extraction and tandem mass spectrometry. Rapid Communications in Mass Spectrometry 2006; 20: 1169.